AMPIO SHAREHOLDERS HAVE AN OPPORTUNITY TO RECOVER THEIR INVESTMENT LOSSES

CLICK HERE TO VIEW THE FIRM RÉSUMÉ OF BERNSTEIN LIEBHARD LLP.

Ampio Pharmaceuticals, Inc.

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) between December 14, 2017 and August 7, 2018. The lawsuit seeks to recover Ampio shareholders’ investment losses.

If you purchased shares of Ampio between December 14, 2017 and August 7, 2018 and would like to join the action, please click “Join Class Action” above.

AMPIO CLASS ACTION: BERNSTEIN LIEBHARD LLP ANNOUNCES THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST AMPIO PHARMACEUTICALS, INC. – AMPE

August 26, 2018.

New York, New York—Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE MKT: AMPE) between December 14, 2017 and August 7, 2018, both dates inclusive (the “Class Period”). The lawsuit seeks to recover Ampio shareholders’ investment losses.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampion; (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On August 7, 2018, during aftermarket hours, Ampio filed a Form 8-K with the SEC providing a regulatory update of the FDA’s review of Ampion, including the AP-003-A trial. Ampio stated that it “met with the FDA in July 2018 and have received a letter in response thereto.” In the letter, “the FDA stated that…that as a single trial the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support a BLA…[and] the FDA does not consider the AP-003-C trial to be an adequate and well-controlled clinical trial.” Ampio stated that “[t]he FDA recommended that [it] perform an additional randomized trial with a concurrent control group and that [it] request a Special Protocol Assessment to obtain FDA concurrence of the trial design before beginning the study.”

On this news, Ampio stock fell $2.25 per share, or over 78%, from its previous closing price to close at $0.61 per share on August 8, 2018, damaging investors.

If you wish to serve as lead plaintiff, you must move the Court no later than October 24, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.